# Budesonide Versus Placebo for the Treatment of Lymphocytic Colitis

> **NCT00217022** · PHASE2,PHASE3 · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 16 (actual)

## Conditions studied

- Lymphocytic Colitis
- Diarrhea

## Interventions

- **OTHER:** Placebo
- **DRUG:** Budesonide

## Key facts

- **NCT ID:** NCT00217022
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-06
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Study closed early, because of low enrollment.
- **Last updated:** 2021-11-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00217022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00217022, "Budesonide Versus Placebo for the Treatment of Lymphocytic Colitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00217022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*